Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs SGS 742 (Primary)
- Indications Inborn error amino acid metabolic disorders
- Focus Therapeutic Use
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2018.
- 08 Jun 2016 Time frame of endpoints changed from 3 years to on-going and phase change from 1/2 to 2 also treatment arms changed from 2 arms to 4 arms.